Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

Shares of Claris Lifesciences climbed 8 percent intraday on Monday on settlement of litigations & licence agreement for anesthetic with US company. Advisory Alert: It has come to our attention ...

Fresenius Kabi is a global leader in supplying blood ... Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept ...

A settlement between Amgen and Fresenius Kabi will permit the biosimilar to launch in mid-2025 in the U.S. The FDA has approved two new denosumab biosimilars that are interchangeable with the ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

In the US, Roche’s Genentech subsidiary filed ... and compositions. Genentech and Fresenius Kabi entered into a settlement agreement in October last year relating to the German company’s ...

The approval concerns Fresenius Kabi's Conexxence and Bomyntra denosumab biosimilars. The German healthcare company said Wednesday that Fresenius Kabi reached a global settlement with Amgen ...

(Reuters) -German healthcare group Fresenius reported fourth-quarter earnings above market expectations on Wednesday, driven ...

(Reuters) - German healthcare group Fresenius reported fourth-quarter adjusted operating profit above market estimates on Wednesday, citing strong performance at its Kabi and Helios divisions.

Fresenius Kabi will be fully responsible for the marketing ... with Evotec providing drug discovery expertise. Researchers in the US have devised a new depot system that could provide months ...

This marks our sixth FDA biosimilar approval, expanding our portfolio to provide more affordable therapies to patients in the U.S.," said Dr. Sang Jin Pak, President Fresenius Kabi Biopharma.